21 institutions hold shares in Citius Pharmaceuticals Inc. (CTXR), with 16.6M shares held by insiders accounting for 22.15% while institutional investors hold 17.84% of the company’s shares. The shares outstanding are 74.95M, and float is at 56.83M with Short Float at 4.26%. Institutions hold 13.89% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 0.57 million shares valued at $0.6 million. The investor’s holdings represent 3.09% of the CTXR Shares outstanding. As of Dec 30, 2020, the second largest holder is HighTower Advisors, LLC with 0.17 million shares valued at $0.17 million to account for 0.92% of the shares outstanding. The other top investors are Argent Wealth Management, LLC which holds 0.16 million shares representing 0.89% and valued at over $0.19 million, while Geode Capital Management, LLC holds 0.78% of the shares totaling 0.14 million with a market value of $0.15 million.
Citius Pharmaceuticals Inc. (NASDAQ: CTXR) is 101.96% higher on its value in year-to-date trading and has touched a low of $0.41 and a high of $1.97 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CTXR stock was last observed hovering at around $1.56 in the last trading session, with the day’s gains setting it 0.5% off its average median price target of $8.00 for the next 12 months. It is also 74.25% off the consensus price target high of $8.00 offered by 1 analysts, but current levels are 74.25% higher than the price target low of $8.00 for the same period.
Currently trading at $2.06, the stock is 54.08% and 71.28% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 154.17 million and changing 32.05% at the moment leaves the stock 90.10% off its SMA200. CTXR registered 146.15% gain for a year compared to 6-month gain of 88.99%. The firm has a 50-day simple moving average (SMA 50) of $1.2798 and a 200-day simple moving average (SMA200) of $1.0891.
The stock witnessed a 55.47% loss in the last 1 month and extending the period to 3 months gives it a 120.39%, and is 51.47% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 15.36% over the week and 12.50% over the month.
Fwd P/E is 1.42. Distance from 52-week low is 396.39% and 4.57% from its 52-week high.
Citius Pharmaceuticals Inc. (CTXR) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Citius Pharmaceuticals Inc. (CTXR) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Citius Pharmaceuticals Inc. is expected to release its quarterly report on 05/14/2021 and quarterly earnings per share for the current quarter are estimated at -$0.06 with sales reaching $19.59M over the same period.The EPS is expected to grow by 42.00% this year.
Citius Pharmaceuticals Inc. (CTXR) Insider Activity
A total of 0 insider transactions have happened at Citius Pharmaceuticals Inc. (CTXR) in the last six months, with sales accounting for 0 and purchases happening 0 times.
Citius Pharmaceuticals Inc. (CTXR): Who are the competitors?
Omeros Corporation (OMER) is 73.65% up on the 1-year trading charts. Short interest in the company’s stock has risen 47.93% from the last report on Dec 30, 2020 to stand at a total of 1.26 million short shares sold with a short interest ratio of 2.04.